Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

Lignende værker

• Novel effector phenotype of Tim-3(+) regulatory T cells leads to enhanced suppressive function in head and neck cancer patients
  af: Liu, Zhuqing, et al.
  Udgivet: (2018)
• Increased PD-1(+) and TIM-3(+) TILs during cetuximab therapy inversely correlates with response in head and neck cancer patients
  af: Jie, Hyun-Bae, et al.
  Udgivet: (2017)
• PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
  af: Shayan, Gulidanna, et al.
  Udgivet: (2015)
• Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
  af: Li, Jing, et al.
  Udgivet: (2016)
• PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer
  af: Kansy, Benjamin A., et al.
  Udgivet: (2017)